Product image of Lenvatinib Accord (Lenvatinib) supplied by GNH India

Lenvatinib Accord

Active Ingredient:
Lenvatinib
Origin:
EU

Lenvatinib Accord (Lenvatinib)

Lenvatinib, the active ingredient in Lenvatinib Accord, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of certain advanced cancers, including differentiated thyroid carcinoma, renal cell carcinoma, and hepatocellular carcinoma, in adult patients.

GNH India supplies Lenvatinib Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global oncology demand. Clients benefit from reliable logistics and comprehensive documentation.

Manufacturer / TM Owner

Accord Healthcare France Sas

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Lenvatinib is used in oncology to inhibit tumor growth pathways in several solid tumor types.
  • Differentiated thyroid carcinoma: reduces disease progression and improves survival in patients with radioactive iodine‑refractory disease.
  • Renal cell carcinoma: slows tumor growth and extends progression‑free survival in advanced clear‑cell renal carcinoma.
  • Hepatocellular carcinoma: delays disease progression and enhances overall survival in patients with unresectable liver cancer.

How It Works

  • Lenvatinib blocks multiple receptor tyrosine kinases—including VEGFR1‑3, FGFR1‑4, PDGFRα, RET and KIT—thereby inhibiting angiogenesis, tumor cell proliferation, and the signaling pathways that drive cancer growth and metastasis.

Side Effects

Lenvatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Hypertension: elevated blood pressure requiring monitoring and management.
  • Diarrhea: may be mild to moderate and manageable with supportive care.
  • Fatigue: persistent tiredness affecting daily activities.
  • Nausea: occasional upset stomach, often controllable with anti‑emetics.
  • Decreased appetite: reduced food intake leading to weight loss.
  • Proteinuria: presence of protein in urine, monitored via urinalysis.

Serious or Rare Side Effects

  • Hepatic failure: severe liver injury requiring immediate discontinuation.
  • Cardiac dysfunction: reduced left‑ventricular ejection fraction or heart failure.
  • Gastrointestinal perforation: risk of ulceration or perforation of the GI tract.
  • Severe hemorrhage: increased bleeding tendency, especially with anticoagulants.
  • Thromboembolic events: arterial or venous clot formation.
  • Fatal infections: opportunistic infections that can be life‑threatening.

Precautions & Warnings

  • When prescribing Lenvatinib, clinicians should consider several safety precautions to minimize risk.
  • Monitor blood pressure: check regularly and treat hypertension promptly.
  • Assess liver function: perform baseline and periodic liver enzyme tests.
  • Evaluate cardiac status: obtain ECG and echocardiogram as indicated.
  • Watch for proteinuria: conduct urine protein assessments during therapy.
  • Avoid use in patients with severe hepatic impairment: contraindicated.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Lenvatinib can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers: may reduce plasma concentrations of lenvatinib.
  • Concomitant use with anticoagulants: increased risk of bleeding.
  • Combination with other VEGF inhibitors: heightened risk of hypertension and proteinuria.

Moderate Interactions (Monitor Closely)

  • Moderate CYP3A4 inhibitors: may increase exposure, monitor for toxicity.
  • Diuretics: may exacerbate electrolyte disturbances.
  • Immunosuppressants: potential for altered immune response.

Frequently Asked Questions

Lenvatinib Accord contains the active ingredient lenvatinib, a tyrosine kinase inhibitor approved for the treatment of differentiated thyroid carcinoma, renal cell carcinoma, and hepatocellular carcinoma in adult patients whose disease has progressed despite standard therapy.

Lenvatinib blocks several receptor tyrosine kinases such as VEGFR1‑3, FGFR1‑4, PDGFRα, RET and KIT. By inhibiting these pathways, it reduces tumor angiogenesis, limits cancer cell proliferation, and interferes with signals that promote tumor growth and metastasis.

The prescribed dose of Lenvatinib Accord is determined by the treating physician based on the specific indication, patient characteristics, and clinical response. Dosing regimens are individualized and should follow the prescriber’s instructions and local labeling.

The safety of lenvatinib in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the drug should be used only if the potential benefit justifies the potential risk to the fetus. Breastfeeding is not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenvatinib uniquely targets a broad spectrum of kinases, including VEGFR, FGFR, PDGFRα, RET and KIT, offering a wider anti‑angiogenic profile compared with agents that focus on fewer receptors. Clinical data suggest comparable or improved efficacy in certain cancers, but safety and tolerability must be weighed against alternative TKIs.

Store at ambient temperature: keep the tablets in the original packaging, protect from moisture and light, and avoid exposure to temperatures above 25 °C. Do not store in the bathroom or near heat sources.

Lenvatinib Accord is taken orally, usually once daily, with or without food as directed by the prescribing clinician. Swallow the tablet whole with a glass of water; do not crush, split, or chew unless specifically instructed.

Serious risks include severe hypertension, hepatic failure, cardiac dysfunction, gastrointestinal perforation, major bleeding, thromboembolic events, and life‑threatening infections. Patients should be monitored closely for these events, and therapy should be discontinued if any occur.

Lenvatinib should be avoided in patients with known hypersensitivity to lenvatinib or any excipients, in those with severe hepatic impairment, and in individuals taking contraindicated strong CYP3A4 inducers. Clinicians must also assess suitability for patients with uncontrolled cardiovascular disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenvatinib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT